GleamWall
中文EN

RANI Rani Therapeutics Holdings, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1856725 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY448.7%
TTM net income YoY-14.6%
TTM EPS YoY90.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-530.5%
Net margin-493.0%
FCF margin-352.7%
EBITDA margin-520.6%

Returns

ROE-248.6%
ROA-103.6%
ROIC (approx.)-173.1%
Asset turnover0.21x

Leverage & solvency

Liabilities / assets21.3%
Debt / equity0.00x
Current ratio5.26x
Interest coverage-71.86x

Cash quality & payout

Operating cash flow / net income0.71x
Accruals ratio-30.2%
Payout ratio—
Capex / revenue3.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.71M$1.71M$1.71M$1.46M$0$0$172,000$1.03M
R&D expense$6.02M$5.02M$5.16M$4.91M$3.22M$5.50M$6.57M$6.81M
SG&A expense$4.91M$5.52M$4.89M$5.09M$4.04M$5.00M$5.62M$5.46M
Operating income-$9.22M-$8.83M-$8.34M-$8.54M-$7.26M-$10.51M-$12.01M-$14.96M
Interest expense$43,000$8,000$88,000$347,000$725,000$877,000$943,000$1.12M
Net income-$7.73M-$7.39M-$7.03M-$10.30M-$5.41M-$6.69M-$7.26M-$8.95M
EBITDA-$9.12M-$8.63M-$8.18M-$8.35M-$7.06M-$10.30M-$11.76M-$14.69M
EPS (basic)-0.04-0.04-0.04—-0.12-0.18-0.22—
EPS (diluted)-0.04-0.04-0.04—-0.12-0.18-0.22—
Weighted avg. shares (diluted)199.01M187.17M180.00M—46.44M36.54M33.44M—
Balance sheet
Cash & equivalents$3.62M$4.87M$9.64M$18.62M$4.14M$10.22M$10.11M$4.26M
Receivables$1.96M$2.04M$2.04M$2.04M——$600,000$0
Current assets$48.48M$56.52M$47.09M$53.32M$4.96M$11.07M$17.78M$29.74M
PP&E, net$659,000$525,000$601,000$736,000$922,000$1.14M$1.35M$1.55M
Total assets$52.53M$60.84M$51.88M$58.62M$10.14M$16.90M$24.12M$36.63M
Current liabilities$9.22M$10.64M$13.86M$12.67M$19.14M$20.62M$20.13M$19.89M
Short-term debt———$0$13.54M$15.00M$15.00M$15.00M
Long-term debt———$0$0$2.23M$5.92M$9.61M
Total debt———$0$13.54M$17.23M$20.92M$24.61M
Total liabilities$11.18M$12.86M$16.34M$17.11M$22.11M$26.05M$29.47M$33.14M
Shareholders' equity$33.97M$39.23M$28.41M$33.01M-$7.86M-$5.58M-$3.06M$1.99M
Net debt———-$18.62M$9.39M$7.01M$10.81M$20.35M
Cash flow statement
Operating cash flow-$7.76M-$9.03M-$6.50M$294,000-$5.06M-$5.80M-$8.15M-$8.65M
Capital expenditure$183,000$32,000$15,000$0$0$37,000$51,000$31,000
Free cash flow-$7.94M-$9.06M-$6.51M$294,000-$5.06M-$5.83M-$8.20M-$8.69M
Investing cash flow$6.86M-$14.56M-$2.45M-$30.97M$0$5.71M$18.23M$2.52M
Financing cash flow-$347,000$18.81M-$27,000$44.85M-$1.01M$188,000-$3.73M$5.62M
Depreciation & amortization$100,000$200,000$161,000$186,000$200,000$200,000$251,000$266,000
Stock-based compensation$2.21M$2.42M$2.08M$2.24M$2.34M$3.29M$3.92M$3.99M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.